Stock Events

Stock Events

Solid Biosciences 

$6.25
0
+$0.1+1.63% Today

Statistics

Day High
6.63
Day Low
6.23
52W High
-
52W Low
-
Volume
322
Avg. Volume
-
Mkt Cap
486.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MarExpected
Q3 2025
Next
-0.5
-0.48
-0.46
-0.44
Expected EPS
-0.503252
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-249.39MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SLDB.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, including Duchenne muscular dystrophy (DMD), directly competing with Solid Biosciences' gene therapy approaches for DMD.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics is involved in the development of genetically targeted therapies for the treatment of rare diseases, including DMD, positioning it as a competitor in the same therapeutic area as Solid Biosciences.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for DMD, making it a direct competitor in the rare disease space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is engaged in the discovery, development, manufacture, and sale of healthcare products, including gene therapies for rare diseases. Its broad focus on gene therapy research can potentially compete with Solid Biosciences' DMD treatments.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, to develop treatments for DMD among other diseases, positioning it as a competitor in the gene therapy space.
Dyadic International DE
DYAI
Mkt Cap40.89M
Dyadic International leverages its proprietary C1 gene expression platform to develop and produce biologic vaccines and drugs at flexible scales, including potential treatments for rare diseases, which may compete with Solid Biosciences' therapeutic approaches.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical focuses on the development of novel products for serious rare and ultra-rare genetic diseases, including muscle-related disorders, which could compete with Solid Biosciences' pipeline.
Abeona Therapeutics
ABEO
Mkt Cap246.65M
Abeona Therapeutics is focused on developing gene and cell therapies for life-threatening rare genetic diseases, including DMD, making it a direct competitor in the gene therapy market.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that, through its acquisition of AveXis, has entered the gene therapy market for spinal muscular atrophy and is exploring treatments for other genetic disorders, potentially competing with Solid Biosciences in the broader gene therapy market.

About

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Ian F. Smith A.C.A., C.P.A.
Employees
100
Country
US
ISIN
US83422E2046

Listings

XNAS
US
SLDB
BOATS
BOATS
SLDB.BOATS

0 Comments

Share your thoughts

FAQ

What is Solid Biosciences stock price today?▼
The current price of SLDB.BOATS is $6.25 USD — it has increased by +1.63% in the past 24 hours. Watch Solid Biosciences stock price performance more closely on the chart.
What is Solid Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Solid Biosciences stocks are traded under the ticker SLDB.BOATS.
What is Solid Biosciences market cap?▼
Today Solid Biosciences has the market capitalization of 486.94M
When is the next Solid Biosciences earnings date?▼
Solid Biosciences is going to release the next earnings report on March 18, 2026.
What were Solid Biosciences earnings last quarter?▼
SLDB.BOATS earnings for the last quarter are -0.48 USD per share, whereas the estimation was -0.44 USD resulting in a -9.34% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Solid Biosciences revenue for the last year?▼
Solid Biosciences revenue for the last year amounts to 0 USD.
What is Solid Biosciences net income for the last year?▼
SLDB.BOATS net income for the last year is -249.39M USD.
How many employees does Solid Biosciences have?▼
As of February 03, 2026, the company has 100 employees.
In which sector is Solid Biosciences located?▼
Solid Biosciences operates in the Health Care sector.
When did Solid Biosciences complete a stock split?▼
Solid Biosciences has not had any recent stock splits.
Where is Solid Biosciences headquartered?▼
Solid Biosciences is headquartered in Charlestown, US.